• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童间质性肺疾病中的表面活性蛋白病。

Surfactant protein disorders in childhood interstitial lung disease.

机构信息

Department of Respiratory Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia.

Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

出版信息

Eur J Pediatr. 2021 Sep;180(9):2711-2721. doi: 10.1007/s00431-021-04066-3. Epub 2021 Apr 11.

DOI:10.1007/s00431-021-04066-3
PMID:33839914
Abstract

Surfactant, which was first identified in the 1920s, is pivotal to lower the surface tension in alveoli of the lungs and helps to lower the work of breathing and prevents atelectasis. Surfactant proteins, such as surfactant protein B and surfactant protein C, contribute to function and stability of surfactant film. Additionally, adenosine triphosphate binding cassette 3 and thyroid transcription factor-1 are also integral for the normal structure and functioning of pulmonary surfactant. Through the study and improved understanding of surfactant over the decades, there is increasing interest into the study of childhood interstitial lung diseases (chILD) in the context of surfactant protein disorders. Surfactant protein deficiency syndrome (SPDS) is a group of rare diseases within the chILD group that is caused by genetic mutations of SFTPB, SFTPC, ABCA3 and TTF1 genes.Conclusion: This review article seeks to provide an overview of surfactant protein disorders in the context of chILD. What is Known: • Surfactant protein disorders are an extremely rare group of disorders caused by genetic mutations of SFTPB, SPTPC, ABCA3 and TTF1 genes. • Given its rarity, research is only beginning to unmask the pathophysiology, inheritance, spectrum of disease and its manifestations. What is New: • Diagnostic and treatment options continue to be explored and evolve in these conditions. • It is, therefore, imperative that we as paediatricians are abreast with current development in this field.

摘要

表面活性剂于 20 世纪 20 年代首次被发现,对于降低肺部肺泡的表面张力至关重要,有助于降低呼吸功并防止肺不张。表面活性蛋白,如表面活性蛋白 B 和表面活性蛋白 C,有助于表面活性剂膜的功能和稳定性。此外,三磷酸腺苷结合盒 3 和甲状腺转录因子 1 对于肺表面活性剂的正常结构和功能也是必不可少的。通过几十年来对表面活性剂的研究和深入了解,人们对表面活性剂蛋白紊乱相关儿童间质性肺疾病(chILD)的研究兴趣日益增加。表面活性剂蛋白缺乏综合征(SPDS)是 chILD 组中一组罕见的疾病,由 SFTPB、SFTPC、ABCA3 和 TTF1 基因突变引起。

结论

本文旨在概述 chILD 背景下的表面活性剂蛋白紊乱。

已知

  1. 表面活性剂蛋白紊乱是一组由 SFTPB、SFTPC、ABCA3 和 TTF1 基因突变引起的极其罕见的疾病。

  2. 由于其罕见性,研究才刚刚开始揭示其病理生理学、遗传、疾病谱及其表现。

新发现

  1. 在这些情况下,诊断和治疗选择仍在不断探索和发展。

  2. 因此,我们儿科医生必须了解该领域的最新发展。

相似文献

1
Surfactant protein disorders in childhood interstitial lung disease.儿童间质性肺疾病中的表面活性蛋白病。
Eur J Pediatr. 2021 Sep;180(9):2711-2721. doi: 10.1007/s00431-021-04066-3. Epub 2021 Apr 11.
2
[Pulmonary surfactant protein adenosine triphosphate-binding-cassette-A3 gene composite mutations in infant congenital interstitial lung disease: report of a case and review of literature].[婴儿先天性间质性肺疾病中肺表面活性物质蛋白三磷酸腺苷结合盒式转运体A3基因复合突变:1例报告并文献复习]
Zhonghua Er Ke Za Zhi. 2016 Oct 2;54(10):761-766. doi: 10.3760/cma.j.issn.0578-1310.2016.10.010.
3
Evaluation and management of inherited disorders of surfactant metabolism.表面活性剂代谢遗传性障碍的评估与管理。
Chin Med J (Engl). 2010 Oct;123(20):2943-7.
4
Heterozygosity for ABCA3 mutations modifies the severity of lung disease associated with a surfactant protein C gene (SFTPC) mutation.ABCA3基因突变的杂合性改变了与表面活性蛋白C基因(SFTPC)突变相关的肺部疾病的严重程度。
Pediatr Res. 2007 Aug;62(2):176-9. doi: 10.1203/PDR.0b013e3180a72588.
5
Ultrastructural characterization of genetic diffuse lung diseases in infants and children: a cohort study and review.婴幼儿和儿童遗传性弥漫性肺疾病的超微结构特征:一项队列研究及综述
Ultrastruct Pathol. 2013 Oct;37(5):356-65. doi: 10.3109/01913123.2013.811454.
6
Surfactant proteins in pediatric interstitial lung disease.小儿间质性肺疾病中的表面活性物质蛋白
Pediatr Res. 2016 Jan;79(1-1):34-41. doi: 10.1038/pr.2015.173. Epub 2015 Sep 16.
7
Inherited pulmonary surfactant metabolism disorders in Argentina: Differences between patients with SFTPC and ABCA3 variants.阿根廷遗传性肺表面活性物质代谢障碍:SFTPC和ABCA3基因变异患者之间的差异。
Pediatr Pulmonol. 2023 Feb;58(2):540-549. doi: 10.1002/ppul.26225. Epub 2022 Nov 11.
8
Population-based frequency of surfactant dysfunction mutations in a native Chinese cohort.在中国人群中基于人群的表面活性剂功能障碍突变的频率。
World J Pediatr. 2016 May;12(2):190-5. doi: 10.1007/s12519-015-0047-x. Epub 2015 Nov 7.
9
Genetics of pediatric interstitial lung disease.小儿间质性肺疾病的遗传学
Curr Opin Pediatr. 2006 Jun;18(3):287-92. doi: 10.1097/01.mop.0000193310.22462.1f.
10
Similarities and differences of interstitial lung disease associated with pathogenic variants in SFTPC and ABCA3 in adults.成人中 SFTPC 和 ABCA3 致病性变异相关的间质性肺疾病的异同。
Respirology. 2024 Apr;29(4):312-323. doi: 10.1111/resp.14667. Epub 2024 Feb 12.

引用本文的文献

1
The lost chILD: a case report of delayed diagnosis of surfactant protein C deficiency in a 15-year-old African male.失亲儿童:一名15岁非洲男性表面活性蛋白C缺乏症延迟诊断的病例报告
Ital J Pediatr. 2025 Jul 7;51(1):212. doi: 10.1186/s13052-025-02018-3.
2
A rare interstitial lung disease in young adulthood due to surfactant protein C gene mutation: Two case reports with brief literature review.一例因表面活性蛋白C基因突变导致的青年罕见间质性肺疾病:两例报告并简要文献综述
Radiol Case Rep. 2025 Jun 12;20(9):4299-4303. doi: 10.1016/j.radcr.2025.05.051. eCollection 2025 Sep.
3
Case of familial interstitial lung disease attributed to ATP-binding cassette transporter 3 gene mutation in identical twins.

本文引用的文献

1
A lung tropic AAV vector improves survival in a mouse model of surfactant B deficiency.一种肺靶向的 AAV 载体可改善表面活性物质 B 缺乏症小鼠模型的存活率。
Nat Commun. 2020 Aug 6;11(1):3929. doi: 10.1038/s41467-020-17577-8.
2
Reversal of Surfactant Protein B Deficiency in Patient Specific Human Induced Pluripotent Stem Cell Derived Lung Organoids by Gene Therapy.基因治疗纠正患者特异性人诱导多能干细胞衍生肺类器官中表面活性蛋白 B 缺乏。
Sci Rep. 2019 Sep 17;9(1):13450. doi: 10.1038/s41598-019-49696-8.
3
Approaching Clinical Trials in Childhood Interstitial Lung Disease and Pediatric Pulmonary Fibrosis.
同卵双胞胎中因ATP结合盒转运体3基因突变导致的家族性间质性肺疾病病例。
Sarcoidosis Vasc Diffuse Lung Dis. 2024 Sep 24;41(3):e2024033. doi: 10.36141/svdld.v41i3.15419.
4
Engraftment of wild-type alveolar type II epithelial cells in surfactant protein C deficient mice.野生型II型肺泡上皮细胞在表面活性蛋白C缺陷小鼠中的植入。
Res Sq. 2024 Sep 13:rs.3.rs-4673915. doi: 10.21203/rs.3.rs-4673915/v1.
5
Biomarkers of lung congestion and injury in acute heart failure.急性心力衰竭中肺充血和损伤的生物标志物。
ESC Heart Fail. 2025 Apr;12(2):781-789. doi: 10.1002/ehf2.14982. Epub 2024 Aug 8.
6
Childhood interstitial lung diseases: current understanding of the classification and imaging findings.儿童间质性肺疾病:分类和影像学表现的最新认识。
Jpn J Radiol. 2024 Sep;42(9):937-952. doi: 10.1007/s11604-024-01603-6. Epub 2024 Jul 16.
7
Abnormal low expression of SFTPC promotes the proliferation of lung adenocarcinoma by enhancing PI3K/AKT/mTOR signaling transduction.SFTPC 异常低表达通过增强 PI3K/AKT/mTOR 信号转导促进肺腺癌的增殖。
Aging (Albany NY). 2023 Nov 12;15(21):12451-12475. doi: 10.18632/aging.205191.
8
Emerging Treatments for Childhood Interstitial Lung Disease.儿童间质性肺疾病的新兴治疗方法。
Paediatr Drugs. 2024 Jan;26(1):19-30. doi: 10.1007/s40272-023-00603-9. Epub 2023 Nov 10.
9
Congenital surfactant protein B (SP-B) deficiency: a case report.先天性表面活性蛋白 B(SP-B)缺乏症:病例报告。
Pan Afr Med J. 2023 Apr 4;44:158. doi: 10.11604/pamj.2023.44.158.35316. eCollection 2023.
10
Congenital Surfactant C Deficiency with Pulmonary Hypertension-A Case Report.先天性表面活性物质C缺乏伴肺动脉高压——病例报告
Children (Basel). 2022 Sep 21;9(10):1435. doi: 10.3390/children9101435.
儿童间质性肺病和小儿肺纤维化临床试验方法探讨
Am J Respir Crit Care Med. 2019 Nov 15;200(10):1219-1227. doi: 10.1164/rccm.201903-0544CI.
4
Children's interstitial and diffuse lung disease.儿童间质性和弥漫性肺疾病。
Lancet Child Adolesc Health. 2019 Aug;3(8):568-577. doi: 10.1016/S2352-4642(19)30117-8. Epub 2019 Jun 18.
5
Advances in synthetic lung surfactant protein technology.合成肺表面活性蛋白技术的进展。
Expert Rev Respir Med. 2019 Jun;13(6):499-501. doi: 10.1080/17476348.2019.1589372. Epub 2019 Mar 6.
6
Side effects of medications used to treat childhood interstitial lung disease.用于治疗儿童间质性肺疾病的药物的副作用。
Paediatr Respir Rev. 2018 Sep;28:68-79. doi: 10.1016/j.prrv.2018.03.002. Epub 2018 Mar 17.
7
Mutations in the thyroid transcription factor gene NKX2-1 result in decreased expression of SFTPB and SFTPC.甲状腺转录因子基因 NKX2-1 的突变导致 SFTPB 和 SFTPC 的表达减少。
Pediatr Res. 2018 Sep;84(3):419-425. doi: 10.1038/pr.2018.30. Epub 2018 Apr 11.
8
Surfactant proteins gene variants in premature newborn infants with severe respiratory distress syndrome.患有严重呼吸窘迫综合征的早产新生儿的表面活性物质蛋白基因变异体
J Perinatol. 2018 Apr;38(4):337-344. doi: 10.1038/s41372-017-0018-2. Epub 2017 Dec 19.
9
The fascinating story of surfactant.表面活性剂的迷人故事。
J Paediatr Child Health. 2017 Apr;53(4):327-332. doi: 10.1111/jpc.13500. Epub 2017 Mar 8.
10
Outcomes of Lung Transplantation for Infants and Children with Genetic Disorders of Surfactant Metabolism.患有表面活性物质代谢遗传疾病的婴幼儿肺移植结果。
J Pediatr. 2017 May;184:157-164.e2. doi: 10.1016/j.jpeds.2017.01.017. Epub 2017 Feb 16.